ovarian neoplasms

Summary

Summary: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Top Publications

  1. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  2. pmc The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
    Robert J Kurman
    Departments of Pathology, Gynecology and Obstetrics and Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Surg Pathol 34:433-43. 2010
  3. ncbi A phase 3 trial of bevacizumab in ovarian cancer
    Timothy J Perren
    St James s Institute of Oncology, St James s University Hospital, Leeds, United Kingdom
    N Engl J Med 365:2484-96. 2011
  4. pmc Identification and characterization of ovarian cancer-initiating cells from primary human tumors
    Shu Zhang
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405, USA
    Cancer Res 68:4311-20. 2008
  5. ncbi A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    Y Miki
    Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
    Science 266:66-71. 1994
  6. ncbi MicroRNA signatures in human ovarian cancer
    Marilena V Iorio
    Molecular Biology Unit, Department of Experimental Oncology, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy
    Cancer Res 67:8699-707. 2007
  7. ncbi Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Tyler J Curiel
    Tulane University Health Science Center, New Orleans, Louisiana 70112, USA
    Nat Med 10:942-9. 2004
  8. ncbi Incorporation of bevacizumab in the primary treatment of ovarian cancer
    Robert A Burger
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 365:2473-83. 2011
  9. ncbi Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    Richard W Tothill
    Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia
    Clin Cancer Res 14:5198-208. 2008
  10. pmc ARID1A mutations in endometriosis-associated ovarian carcinomas
    Kimberly C Wiegand
    British Columbia Cancer Agency, Vancouver, Canada
    N Engl J Med 363:1532-43. 2010

Detail Information

Publications280 found, 100 shown here

  1. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  2. pmc The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
    Robert J Kurman
    Departments of Pathology, Gynecology and Obstetrics and Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Surg Pathol 34:433-43. 2010
    ..tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms. Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-..
  3. ncbi A phase 3 trial of bevacizumab in ovarian cancer
    Timothy J Perren
    St James s Institute of Oncology, St James s University Hospital, Leeds, United Kingdom
    N Engl J Med 365:2484-96. 2011
    ..Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease...
  4. pmc Identification and characterization of ovarian cancer-initiating cells from primary human tumors
    Shu Zhang
    Medical Sciences, Indiana University School of Medicine, Bloomington, Indiana 47405, USA
    Cancer Res 68:4311-20. 2008
    ..Based on these findings, we assert that epithelial ovarian cancers derive from a subpopulation of CD44(+)CD117(+) cells, thus representing a possible therapeutic target for this devastating disease...
  5. ncbi A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    Y Miki
    Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
    Science 266:66-71. 1994
    ..Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology...
  6. ncbi MicroRNA signatures in human ovarian cancer
    Marilena V Iorio
    Molecular Biology Unit, Department of Experimental Oncology, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy
    Cancer Res 67:8699-707. 2007
    ..Our results indicate that miRNAs might play a role in the pathogenesis of human EOC and identify altered miRNA gene methylation as a possible epigenetic mechanism involved in their aberrant expression...
  7. ncbi Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Tyler J Curiel
    Tulane University Health Science Center, New Orleans, Louisiana 70112, USA
    Nat Med 10:942-9. 2004
    ..This specific recruitment of T(reg) cells represents a mechanism by which tumors may foster immune privilege. Thus, blocking T(reg) cell migration or function may help to defeat human cancer...
  8. ncbi Incorporation of bevacizumab in the primary treatment of ovarian cancer
    Robert A Burger
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 365:2473-83. 2011
    ..Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy...
  9. ncbi Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    Richard W Tothill
    Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia
    Clin Cancer Res 14:5198-208. 2008
    ..The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features...
  10. pmc ARID1A mutations in endometriosis-associated ovarian carcinomas
    Kimberly C Wiegand
    British Columbia Cancer Agency, Vancouver, Canada
    N Engl J Med 363:1532-43. 2010
    ..Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis, but the molecular events involved in this transformation have not been described...
  11. ncbi Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia 19104, USA
    N Engl J Med 348:203-13. 2003
    ..Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established...
  12. ncbi MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN
    Hua Yang
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    Cancer Res 68:425-33. 2008
    ..These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway...
  13. pmc Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma
    Sian Jones
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 330:228-31. 2010
    ..In a total of 42 OCCCs, 7% had mutations in PPP2R1A and 57% had mutations in ARID1A. These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC...
  14. pmc microRNAs exhibit high frequency genomic alterations in human cancer
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 103:9136-41. 2006
    ..These findings support the notion that copy number alterations of miRNAs and their regulatory genes are highly prevalent in cancer and may account partly for the frequent miRNA gene deregulation reported in several tumor types...
  15. pmc The biology of ovarian cancer: new opportunities for translation
    Robert C Bast
    Departments of Experimental Therapeutics and Systems Biology, University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA
    Nat Rev Cancer 9:415-28. 2009
    ....
  16. pmc Rethinking ovarian cancer: recommendations for improving outcomes
    Sebastian Vaughan
    Ovarian Cancer Action Research Centre, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, UK
    Nat Rev Cancer 11:719-25. 2011
    ..Nine major recommendations are outlined in this Opinion article...
  17. pmc Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm
    Robert J Kurman
    Division of Gynecologic Pathology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Hum Pathol 42:918-31. 2011
    ..If this concept is confirmed, it leads to the conclusion that the only true primary ovarian neoplasms are gonadal stromal and germ cell tumors analogous to testicular tumors...
  18. pmc Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    Eiichi Sato
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:18538-43. 2005
    ..We conclude that intraepithelial CD8+ TILs and a high CD8+/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer...
  19. pmc OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 30:2039-45. 2012
    ....
  20. ncbi MicroRNA expression profiles in serous ovarian carcinoma
    Eun Ji Nam
    Women s Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
    Clin Cancer Res 14:2690-5. 2008
    ..We assessed the expression of microRNA and the association between microRNA expression and the prognosis of serous ovarian carcinoma...
  21. pmc BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
    Kathryn Alsop
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    J Clin Oncol 30:2654-63. 2012
    ..The impact of germ-line mutation on response requires further investigation to understand its impact on treatment planning and clinical trial design...
  22. pmc Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production
    Karen McLean
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    J Clin Invest 121:3206-19. 2011
    ..Taken together, our data suggest that MSCs in the ovarian tumor microenvironment have an expression profile that promotes tumorigenesis and that BMP inhibition may be an effective therapeutic approach for ovarian cancer...
  23. pmc Ovarian cancer development and metastasis
    Ernst Lengyel
    Department of Obstetrics and Gynecology Section of Gynecologic Oncology, University of Chicago, Chicago, IL 60637, USA
    Am J Pathol 177:1053-64. 2010
    ....
  24. pmc Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance
    Ayesha B Alvero
    Department of Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cell Cycle 8:158-66. 2009
    ..The identification and cloning of human OCSCs can aid in the development of better therapeutic approaches for ovarian cancer patients...
  25. pmc Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
    Paul P Szotek
    Pediatric Surgical Research Laboratories, Department of Surgery, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 103:11154-9. 2006
    ..In the future, individualized therapy must incorporate analysis of the stem cell-like subpopulation of ovarian cancer cells when designing therapeutic strategies for ovarian cancer patients...
  26. ncbi Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
    Mary Claire King
    Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195, USA
    Science 302:643-6. 2003
    ..Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 mutation carriers. Physical exercise and lack of obesity in adolescence were associated with significantly delayed breast cancer onset...
  27. pmc Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis
    Ie Ming Shih
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Pathol 164:1511-8. 2004
    ..This model of carcinogenesis reconciles the relationship of borderline tumors to invasive carcinoma and provides a morphological and molecular framework for studies aimed at elucidating the pathogenesis of ovarian cancer...
  28. ncbi The genesis and evolution of high-grade serous ovarian cancer
    David D L Bowtell
    Peter MacCallum Cancer Centre, Department of Biochemistry, University of Melbourne, Melbourne 3002, Australia
    Nat Rev Cancer 10:803-8. 2010
    ..These findings suggest a model in which homologous recombination repair deficiency initiates a cascade of molecular events that sculpt the evolution of high-grade serous ovarian cancer and dictate its response to therapy...
  29. ncbi MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth
    David C Corney
    Department of Biomedical Sciences and Microarray Core Facility, Cornell University, Ithaca, New York, USA
    Cancer Res 67:8433-8. 2007
    ..Taken together, these results show the existence of a novel mechanism by which p53 suppresses such critical components of neoplastic growth as cell proliferation and adhesion-independent colony formation...
  30. ncbi Cancer susceptibility and the functions of BRCA1 and BRCA2
    Ashok R Venkitaraman
    University of Cambridge, CRC Department of Oncology, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cell 108:171-82. 2002
    ..Here, I examine what is known about the biological functions of the BRCA proteins and ask how their disruption can induce susceptibility to specific types of cancer...
  31. ncbi Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer
    Sharmila A Bapat
    National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra 411007, India
    Cancer Res 65:3025-9. 2005
    ....
  32. pmc Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
    Celeste Leigh Pearce
    Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
    Lancet Oncol 13:385-94. 2012
    ..We undertook an international collaborative study to assess the association between endometriosis and histological subtypes of ovarian cancer...
  33. pmc Stem cell pathways contribute to clinical chemoresistance in ovarian cancer
    Adam D Steg
    Department of Obstetrics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Clin Cancer Res 18:869-81. 2012
    ..However, whether these populations are more capable of surviving chemotherapy in de novo tumors is unknown...
  34. pmc Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
    Ilona Kryczek
    Department of Surgery, University of Michigan, Ann Arbor, MI 48109 0669, USA
    Blood 114:1141-9. 2009
    ..This study thus provides scientific and clinical rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients...
  35. pmc Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral
    S V Tavtigian
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    J Med Genet 43:295-305. 2006
    ..However, clinical testing methods with high sensitivity for deleterious mutations in these genes also detect many unclassified variants, primarily missense substitutions...
  36. ncbi The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform
    Kimberly E Resnick
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
    Gynecol Oncol 112:55-9. 2009
    ..To determine the utility of serum miRNAs as biomarkers for epithelial ovarian cancer...
  37. ncbi Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
    Alfons Meindl
    Department of Obstetrics and Gynecology, Division of Tumor Genetics, Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munich, Germany
    Nat Genet 42:410-4. 2010
    ..These results provide the first unambiguous evidence of highly penetrant mutations associated with human cancer in a RAD51 paralog and support the 'common disease, rare allele' hypothesis...
  38. ncbi Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Andrea H Bild
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Nature 439:353-7. 2006
    ..Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics...
  39. pmc Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers
    Shan Deng
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e10277. 2010
    ..As a novel cancer stem cell marker, ALDH1 can be used for tumors whose corresponding normal tissues express ALDH1 in relatively restricted or limited levels such as breast, lung, ovarian or colon cancer...
  40. pmc Development of a multimarker assay for early detection of ovarian cancer
    Zoya Yurkovetsky
    University of Pittsburgh Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213, USA
    J Clin Oncol 28:2159-66. 2010
    ..Early detection of ovarian cancer has great promise to improve clinical outcome...
  41. ncbi Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287 1248, USA
    J Clin Oncol 20:1248-59. 2002
    ..To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy...
  42. pmc Dicer, Drosha, and outcomes in patients with ovarian cancer
    William M Merritt
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    N Engl J Med 359:2641-50. 2008
    ..We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer...
  43. ncbi Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  44. pmc Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
    Ahmed Ashour Ahmed
    Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK
    J Pathol 221:49-56. 2010
    ..Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance...
  45. pmc Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
    Kelly L Bolton
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    JAMA 307:382-90. 2012
    ..A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of BRCA1 remains unclear...
  46. ncbi The changing view of high-grade serous ovarian cancer
    Els M J J Berns
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Res 72:2701-4. 2012
    ..Inactivation of genes associated with DNA damage repair underlies responses to platinum and PARP inhibitors. Here we review these recent developments...
  47. ncbi Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells
    Nawneet K Kurrey
    National Centre for Cell Science, NCCS Complex, Pune University Campus, Pune, India
    Stem Cells 27:2059-68. 2009
    ....
  48. ncbi Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Robert F Ozols
    Medical Science Department, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 21:3194-200. 2003
    ..Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population...
  49. ncbi Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, USA
    N Engl J Med 354:34-43. 2006
    ..The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer...
  50. pmc Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
    Martin Köbel
    Department of Pathology, Genetic Pathology Evaluation Centre of the Prostate Research Centre, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    PLoS Med 5:e232. 2008
    ..We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis...
  51. pmc Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression
    Erika L Spaeth
    Department of Stem Cell Transplantation and Cellular Therapy, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 4:e4992. 2009
    ..There are several suggested origins of the TAF including tissue-resident, circulating, and epithelial-to-mesenchymal-transitioned cells...
  52. ncbi Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  53. ncbi Germline mutations in RAD51D confer susceptibility to ovarian cancer
    Chey Loveday
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, UK
    Nat Genet 43:879-82. 2011
    ..Moreover, we show that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD51D mutation carriers...
  54. ncbi Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    E Y Woo
    Department of Surgery, Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 61:4766-72. 2001
    ..These observations provide evidence for the contribution of regulatory T cells to immune dysfunction in cancer patients...
  55. ncbi Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections
    Sergio Marchini
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Lancet Oncol 12:273-85. 2011
    ..We profiled miRNA expression in stage I EOC tumours to assess whether there is a miRNA signature associated with overall and progression-free survival (PFS) in stage I EOC...
  56. ncbi Ovarian cancer: strategies for overcoming resistance to chemotherapy
    Roshan Agarwal
    Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
    Nat Rev Cancer 3:502-16. 2003
    ..A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved...
  57. pmc Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells
    Lilly Y W Bourguignon
    Department of Medicine, University of California, San Francisco, and Endocrine Unit, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Biol Chem 283:17635-51. 2008
    ....
  58. pmc Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival
    Ines A Silva
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 71:3991-4001. 2011
    ..Taken together, our findings define ALDH and CD133 as a functionally significant set of markers to identify ovarian CSCs...
  59. pmc Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer
    Charles N Landen
    Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Mol Cancer Ther 9:3186-99. 2010
    ..This enzyme may be important for identification and targeting of chemoresistant cell populations in ovarian cancer...
  60. ncbi Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    M William Audeh
    Samuel Oschin Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Lancet 376:245-51. 2010
    ..We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations...
  61. ncbi ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome
    Yu Chi Wang
    Laboratory of Epigenetics and Cancer Stem Cells, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Am J Pathol 180:1159-69. 2012
    ..The use of a combination of ALDH1 with other stem cell markers may help define ovarian cancer stem cells more stringently...
  62. pmc Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
    Lin Zhang
    Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 105:7004-9. 2008
    ..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer...
  63. pmc Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2
    Sian Rizzo
    Section of Medicine, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Mol Cancer Ther 10:325-35. 2011
    ..As such, EZH2 is an important target for anticancer drug development...
  64. ncbi MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
    Douglas D Taylor
    Department of Obstetrics, Gynecology, and Women s Health, University of Louisville School of Medicine, Louisville, KY 40202, USA
    Gynecol Oncol 110:13-21. 2008
    ..Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes...
  65. pmc Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
    Tom Walsh
    Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 108:18032-7. 2011
    ..Clinical genetic testing is currently done gene by gene, with each test costing thousands of dollars. In contrast, massively parallel sequencing allows such testing for many genes simultaneously at low cost...
  66. ncbi Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile
    Ardian Latifi
    Women s Cancer Research Centre, Royal Women s Hospital, Victoria 3052, Australia
    J Cell Biochem 112:2850-64. 2011
    ....
  67. ncbi Mutation of the PIK3CA gene in ovarian and breast cancer
    Ian G Campbell
    VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer Res 64:7678-81. 2004
    ..5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Our study is the first direct evidence that PIK3CA is an oncogene in ovarian cancer and greatly extends recent findings in breast cancer...
  68. ncbi CD133 expression defines a tumor initiating cell population in primary human ovarian cancer
    Michael D Curley
    Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Stem Cells 27:2875-83. 2009
    ..Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer...
  69. ncbi Early events in the pathogenesis of epithelial ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    J Clin Oncol 26:995-1005. 2008
    ....
  70. ncbi Role of microRNAs in drug-resistant ovarian cancer cells
    Antonio Sorrentino
    Department of Hematology, Istituto Superiore di Sanita, Rome, Italy
    Gynecol Oncol 111:478-86. 2008
    ..This work was aimed to identify selected microRNAs involved in the development of chemoresistance in ovarian cancer...
  71. pmc A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
    Ellen L Goode
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Genet 42:874-9. 2010
    ..Analysis of HOXD1, MYC, TIPARP and SKAP1 at these loci and of BNC2 at 9p22 supports a functional role for these genes in ovarian cancer development...
  72. ncbi Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
    Sergio Marchini
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy
    Eur J Cancer 49:520-30. 2013
    ..The present study is aimed to identify genetic pathways correlated with chemoresistance in epithelial ovarian cancer (EOC)...
  73. ncbi Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers
    Alireza Heravi-Moussavi
    British Columbia Cancer Research Centre, Vancouver, BC, Canada
    N Engl J Med 366:234-42. 2012
    ..Mutation carriers are at risk for nonepithelial ovarian tumors, notably sex cord-stromal tumors...
  74. ncbi CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells
    M Q Gao
    Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea
    Oncogene 29:2672-80. 2010
    ..These findings will have important clinical applications for developing effective therapeutic strategies to treat ovarian cancer...
  75. ncbi Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer
    S Peng
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510, USA
    Oncogene 29:2153-9. 2010
    ....
  76. ncbi Ovarian cancer stem cell markers: prognostic and therapeutic implications
    Daniela Burgos-Ojeda
    University of Michigan, Cell and Molecular Biology Program, United States
    Cancer Lett 322:1-7. 2012
    ....
  77. ncbi Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
    David W Kindelberger
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 31:161-9. 2007
    ....
  78. ncbi Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:2512-9. 2010
    ..Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers...
  79. ncbi The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  80. pmc Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
    A Antoniou
    Cancer Research U K Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom
    Am J Hum Genet 72:1117-30. 2003
    ..The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers...
  81. ncbi Worldwide burden of gynaecological cancer: the size of the problem
    R Sankaranarayanan
    International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon 69008, France
    Best Pract Res Clin Obstet Gynaecol 20:207-25. 2006
    ..Political will and advocacy to invest in healthcare infrastructure and human resources to improve service delivery and accessibility are vital to reduce the current burden in low- and medium-resource countries...
  82. ncbi IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
    Michael S Anglesio
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 17:2538-48. 2011
    ..We analyze here the most comprehensive gene expression and copy number data sets, to date, to identify potential therapeutic targets of OCCA...
  83. pmc Meta-analysis of BRCA1 and BRCA2 penetrance
    Sining Chen
    Departments of Environmental Health Sciences and Biostatistics, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Clin Oncol 25:1329-33. 2007
    ..Such penetrance has been investigated by studies worldwide. The reported estimates vary. To facilitate clinical management and counseling of the at-risk population, we address this issue through a meta-analysis...
  84. pmc A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2
    Samuel C Mok
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 16:521-32. 2009
    ..Increased MAGP2 expression correlated with microvessel density suggesting a proangiogenic role in vivo. Thus, MAGP2 may serve as a survival-associated target...
  85. ncbi Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
    Gad Singer
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Natl Cancer Inst 95:484-6. 2003
    ..The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways...
  86. ncbi Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Rockledge, PA, USA
    J Clin Oncol 21:283-90. 2003
    ..To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma...
  87. ncbi Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer
    Nuzhat Ahmed
    Women s Cancer Research Centre, Royal Women s Hospital, Melbourne, Australia
    Curr Cancer Drug Targets 10:268-78. 2010
    ..We propose the molecular targeting of distinct 'EMT transformed cancer stem-like cells' and suggest ways that may improve the efficacy of current chemotherapeutic regimens much needed for the management of this disease...
  88. ncbi TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
    Michael G Kelly
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cancer Res 66:3859-68. 2006
    ..In addition, we provide new evidence that links TLR-4 signaling, inflammation, and chemoresistance in ovarian cancer cells...
  89. ncbi Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    M K B Parmar
    Lancet 361:2099-106. 2003
    ..There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment...
  90. ncbi Ovarian cancer
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 374:1371-82. 2009
    ....
  91. pmc A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2
    Honglin Song
    Cancer Research UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
    Nat Genet 41:996-1000. 2009
    ..82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73-0.81, P(trend) = 4.1 x 10(-21))...
  92. pmc Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems
    Russell Vang
    Department of Pathology Division of Gynecologic Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Adv Anat Pathol 16:267-82. 2009
    ..This review provides an update on the pathogenesis and clinicopathologic features of these 2 types of serous carcinomas and addresses some of the diagnostic problems that are encountered in routine practice...
  93. pmc Common variants at 19p13 are associated with susceptibility to ovarian cancer
    Kelly L Bolton
    Department of Oncology, University of Cambridge, Cambridge, UK
    Nat Genet 42:880-4. 2010
    ..Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development...
  94. pmc Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"
    Sharon E Johnatty
    Queensland Institute of Medical Research, Brisbane, Australia
    PLoS Genet 6:e1001016. 2010
    ..ORper-allele 1.14 (1.04-1.24) p=0.003]. Our study adds to the growing evidence that, like the 8q24 locus, the telomerase reverse transcriptase locus at 5p15.33, is a general cancer susceptibility locus...
  95. pmc Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
    Panagiotis A Konstantinopoulos
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 28:3555-61. 2010
    ..To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC)...
  96. pmc Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School, Brown University, Providence, RI, USA
    Am J Obstet Gynecol 203:228.e1-6. 2010
    ..We sought to compare the Risk of Malignancy Index (RMI) to the Risk of Ovarian Malignancy Algorithm (ROMA) to predict epithelial ovarian cancer (EOC) in women with a pelvic mass...
  97. pmc Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets
    Kosuke Yoshihara
    Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    PLoS ONE 5:e9615. 2010
    ..Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer...
  98. pmc E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer
    Narasimhan Kothandaraman
    Diagnostic Biomarker Discovery Laboratory, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University Health System, 5 Lower Kent Ridge Road, 119074, Singapore
    BMC Cancer 10:64. 2010
    ....
  99. ncbi Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas
    Neali D Hendrix
    Department of Pathology, University of Michigan Medical School, 210 Washtenaw Avenue, Ann Arbor, MI 48109, USA
    Cancer Res 66:1354-62. 2006
    ..Our findings support the notion that FGF9 is a key factor contributing to the cancer phenotype of OEAs carrying Wnt/beta-catenin pathway defects...
  100. ncbi Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
    Bradley J Monk
    University of California at Irvine UCI and UCI Medical Center, Orange, CA 92868 3298, USA
    J Clin Oncol 28:3107-14. 2010
    ....
  101. ncbi Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...

Research Grants62

  1. Cancer induction in the ovary by an environmental pollutant, dibenzo[a,l]pyrene
    Kun Ming Chen; Fiscal Year: 2013
    ..the optimal dose for DB[a,l]P to induce ovarian cancer more specifically, and c. the effect of DB[a,l]P on molecular markers which are important in human ovarian cancer development. ..
  2. Development and Pilot Test of an Elective BSO Decision Support Guide
    Miriam Kuppermann; Fiscal Year: 2010
    ..the risk of ovarian cancer and/or to avoid possible morbidities and future surgery related to benign ovarian neoplasms, endometriosis, and pelvic pain...
  3. HuR Targeted Nanotherapy for Lung Cancer
    Rajagopal Ramesh; Fiscal Year: 2013
    ..Aim 3: Determine the efficacy of HuR-TfNPs treatment in combination with small molecule inhibitors in vitro and in vivo. The outcome of our studies will result in advanced preclinical testing and translation to the clinic. ..
  4. Validation of an Antibody Test for Early Diagnosis of Ovarian Cancer
    Michael A Tainsky; Fiscal Year: 2013
    ....
  5. Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas
    Xiongbin Lu; Fiscal Year: 2013
    ....
  6. Diagnosis of Ovarian Cancer by Confocal Microendoscopy
    Arthur F Gmitro; Fiscal Year: 2013
    ..In addition to the technology development and clinical translation, another aim of the project is to develop and test targeted contrast agents that provide safer and more effective in vivo identification of ovarian cancer. ..
  7. Breast and Ovary Cancer Clinical Validation Center
    Christopher I Li; Fiscal Year: 2013
    ..Based on Studies 2 and 3, Study 4 will validate ovary cancer markers and screening decision rules in an independent set of WHI serial preclinical samples, a setting in which no ovary cancer screening occurred. ..
  8. PHARMACODYNAMIC PHASE II BREAST, LUNG AND OVARY TRIALS
    James Doroshow; Fiscal Year: 2001
    ....
  9. ENDOGENOUS STEROIDS AND CANCER OF THE OVARY
    Paolo Toniolo; Fiscal Year: 2001
    ..Controls will be women randomly selected from among all eligible individuals from the same cohorts and matching a given case on specified criteria. The study duration will be three years. ..
  10. Progestogen Inhibition of Ovarian Cancer Cell Metastasis
    William Murdoch; Fiscal Year: 2003
    ....
  11. In-Vivo Optical Imaging of Chemically Targeted Tumor Tis
    KARIM JALLAD; Fiscal Year: 2003
    ..Thus this Phase I project is the basis for subsequent human medical trials to be carried out at the Indiana University Medical School in Phase II. ..
  12. Clinical evaluation of an anti-mesothelin immunotoxin
    Raffit Hassan; Fiscal Year: 2002
    ..The proposed research and training will allow me to become an independent investigator involved in developing and evaluating new biologic agents in patients with cancer. ..
  13. PROSTATE, LUNG, COLORECTAL & OVARIAN CANCER
    Edward Gelmann; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  14. CASE CONTROL STUDY OF BENIGN OVARIAN NEOPLASMS
    Carolyn Westhoff; Fiscal Year: 1993
    ..Analyses will be performed separately for each of the major tumor types, and will be stratified by the usual frequency and source of gynecological care...
  15. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
    E Crawford; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  16. PROSTATE, LUNG, COLORECTAL & OVARIAN (PLCO) CANCER
    Gerald Andriole; Fiscal Year: 2001
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  17. PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER
    Raymond Demers; Fiscal Year: 2001
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  18. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
    Timothy Church; Fiscal Year: 2001
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  19. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
    Douglas Reding; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  20. SEROLOGIC SERBBL IN HEALTHY WOMEN
    ANDRE BARON; Fiscal Year: 2000
    ..Moreover, ErbB1 receptors are commonly amplified and/or over-expressed in ovarian neoplasms of epithelial origin, where increased signaling may contribute to cellular transformation...
  21. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
    Joel Weissfeld; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  22. PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER
    Lance Yokochi; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  23. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
    Saundra Buys; Fiscal Year: 2000
    ..A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays. ..
  24. CASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGY
    Harvey Risch; Fiscal Year: 2002
    ....
  25. PROSTATE, LUNG, COLORECTAL, & OVARIAN CANCER SCREENING
    BARBARA O BRIEN; Fiscal Year: 2000
    ..The CC in its coordination efforts acts as a liaison between the Screening Centers, the Central Blood Testing Facility (LAB), study consultants, and the National Cancer Institute Project Officers. ..
  26. DNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDY
    Harvey Risch; Fiscal Year: 2002
    ..abstract_text> ..
  27. SFV MEDIATED ONCOGENE KNOCKOUT FOR CHEMOSENSITIZATION
    Gene Siegal; Fiscal Year: 2000
    ..technique can be developed as a means to achieve enhanced chemosensitization as a therapeutic modality for ovarian neoplasms of epithelial origin...
  28. IDENTIFICATION OF PROSTATE AND OVARIAN CANCER MARKERS
    Yingming Zhao; Fiscal Year: 2003
    ..Thus, this research will contribute to prolonging survival and reducing mortality of prostate and ovarian cancer patients. ..
  29. Acrogranin Function in the Ovary
    Laura Diaz Cueto; Fiscal Year: 2006
    ..A rational design of selective reagents that target the acrogranin pathway should afford new therapeutics targets for human cancer where acrogranin has a role. [unreadable] [unreadable] [unreadable]..
  30. ADVANCED GENERATION VECTORS FOR CANCER GENE THERAPY
    Victor Krasnykh; Fiscal Year: 2000
    ..proposed commercial application: not available ..
  31. Biobehavioral-Cytokine Interactions in Ovarian Cancer
    Susan Lutgendorf; Fiscal Year: 2007
    ..Findings will have implications for innovative behavioral and pharmacological intervention strategies for ovarian cancer patients. ..
  32. Ovarian Cancer and Mismatch Repair Deficiency
    Tuya Pal; Fiscal Year: 2009
    ..abstract_text> ..
  33. Healing Touch and Immunity in Advanced Cervical Cancer
    Susan Lutgendorf; Fiscal Year: 2002
    ....
  34. Healing Touch, Immunity, and Fatigue in Breast Cancer
    Susan Lutgendorf; Fiscal Year: 2004
    ....
  35. Prognostic Markers for Juvenile Pilocytic Astrocytomas
    Kwong Kwok Wong; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  36. The Feasibility of Earlier Detection of Ovarian Cancer Using Symptom Reports
    Marin Andersen; Fiscal Year: 2009
    ..Outcomes of such an approach for women with and without the identified pattern of symptoms will be examined. ..
  37. MUC-1 related cancer immunity: determinants and predictive significance
    Daniel Cramer; Fiscal Year: 2009
    ..The findings of our study could provide the basis for developing a safe cancer- preventing vaccine for ovarian cancer and perhaps other MUC1-expressing tumors. ..
  38. A Pooled Analysis to Identify New Ovarian Cancer Risk Factors
    Celeste Leigh Pearce; Fiscal Year: 2010
    ..Gaining a better understanding of ovarian cancer, which this project will provide, is critical to identifying women at risk and for improving the outcome for women who are diagnosed with this disease. ..
  39. KINSHIP AND SOCIO-DEMOGRAPHIC DETERMINANTS OF MORTALITY
    Ken Smith; Fiscal Year: 2002
    ..To accomplish the proposed aims, the set of Utah death certificates within the Utah Population Database will be expanded to include about 500,000 death records that cover the period 1904-1995. ..
  40. Genes, Hormones & Environment in an Ovarian Cancer Model
    Daniel Cramer; Fiscal Year: 2007
    ..Our continued goal is to identify modifiable risk factors and chemo preventive agents for a common and lethal cancer in women. ..
  41. EPIDEMIOLOGIC AND BIOLOGIC PREDICTORS OF IVF SUCCESS
    Daniel Cramer; Fiscal Year: 2002
    ....
  42. Cellular gene expression in HPV associated neoplasia
    Christopher Crum; Fiscal Year: 2002
    ..Such methods, if successful, could conceivably revolutionize the approach to cervical cancer prevention by broadening the conditions under which screening could be conducted. ..
  43. Risk for New onset of Depression in Perimenopausal Women
    Daniel Cramer; Fiscal Year: 2009
    ..abstract_text> ..
  44. Ovarian Cancer and Gonadotropin Signaling
    CELESTE PEARCE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  45. The Progesterone Receptor Gene and Ovarian Cancer Risk
    CELESTE PEARCE; Fiscal Year: 2005
    ..We will also test our previous two case-control studies for any additional identified SNPs, including 326 cases and 493 controls (many of the SNPs have already been tested in these populations). ..
  46. MESOTHELIN ANTIGENS FOR DIAGNOSIS/THERAPY OF OVARIAN CA
    Ingegerd Hellstrom; Fiscal Year: 2003
    ..As part of this study, she shall investigate whether the soluble MR molecule (SMR) can act as an inhibitor of the immune response and, if so, whether the inhibition can be overcome. ..
  47. SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES
    Robert Bast; Fiscal Year: 2004
    ....
  48. Evaluation of Chemotherapy Claims for Breast Cancer
    Xianglin Du; Fiscal Year: 2003
    ....
  49. Flavopiridol Targets Transcription Factor/DNA Complexes
    Keith Bible; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  50. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
  51. AhR and reproductive aging
    BRIAN PETROFF; Fiscal Year: 2008
    ..This project will provide crucial knowledge for the identification and prevention of infertility and birth defects due to the AhR pathway in older mothers. [unreadable] [unreadable] [unreadable]..
  52. Coactivation of Estrogen Receptor alpha/Sp1
    Stephen Safe; Fiscal Year: 2006
    ..abstract_text> ..
  53. Breast stem cell analysis in random periareolar fine needle aspirates from high r
    BRIAN PETROFF; Fiscal Year: 2008
    ..Overall, this work has the potential to improve our understanding of breast stem cells and cancer risk and refine breast cancer prevention through a novel stem cell-targeted approach. [unreadable] [unreadable] [unreadable]..
  54. BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY
    Smita Bhatia; Fiscal Year: 2003
    ..g., second cancers, births, cardiac complications, etc.) that may have occurred since the completion of the initial questionnaire. ..
  55. Development of Digital SNP Analysis in Cancer Detection
    Ie Ming Shih; Fiscal Year: 2005
    ..Thus, the encouraging results from this study will ensure the detection of AI in plasma a promising cancer research direction for further exploration. ..